WO2014010654A2 - スルホンアミド化合物の組み合わせ - Google Patents
スルホンアミド化合物の組み合わせ Download PDFInfo
- Publication number
- WO2014010654A2 WO2014010654A2 PCT/JP2013/068927 JP2013068927W WO2014010654A2 WO 2014010654 A2 WO2014010654 A2 WO 2014010654A2 JP 2013068927 W JP2013068927 W JP 2013068927W WO 2014010654 A2 WO2014010654 A2 WO 2014010654A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- intraocular pressure
- glaucoma
- preventive
- compound
- therapeutic agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to the prevention or treatment of (6- ⁇ [4- (pyrazol-1-yl) benzyl] (pyridin-3-ylsulfonyl) aminomethyl ⁇ pyridin-2-ylamino) acetate and other glaucoma or ocular hypertension.
- the present invention relates to a preventive or therapeutic agent for glaucoma or ocular hypertension combined with a drug, or an intraocular pressure lowering agent.
- Glaucoma is a refractory eye disease that can lead to blindness due to increased intraocular pressure due to various etiologies and damage to internal tissues of the eyeball (retinal, optic nerve, etc.).
- intraocular pressure lowering therapy is generally used, and representative examples include drug therapy, laser therapy, and surgical therapy.
- sympathomimetics nonselective stimulants such as dipivefrin, alpha 2 receptor agonists, such as brimonidine
- sympatholytic timolol, befunolol, carteolol, nipradilol, betaxolol, levobunolol, Mechipurano roll (Metipranolol) beta receptor blockers such, alpha 1 receptor blockers such bunazosin hydrochloride
- parasympathetic agonists such as pilocarpine
- carbonic anhydrase inhibitors acetazolamide
- prostaglandins isopropyl Uno Drugs such as prostone, latanoprost, travoprost, bimatoprost
- Rho kinase inhibitors such as SNJ-1656
- adenosine agonists such as INO-8875
- serotonin blockers BVT-28949
- EP2 agonist prostaglandin E2 receptor subtype 2 agonist
- Patent Document 2 Japanese Patent No. 2726672 (Patent Document 2) reports the administration of a combination of a sympathetic nerve blocker and a prostaglandin.
- Patent Document 3 discloses a method for treating glaucoma by administering a combination of several drugs having an action of lowering intraocular pressure to the eye.
- Patent Document 4 discloses administration of a combination of a Rho kinase inhibitor and prostaglandins
- Patent Document 5 discloses a Rho kinase inhibitor. And the combination of ⁇ receptor blockers have been reported.
- preventive or therapeutic agents for glaucoma or ocular hypertension are non-selective sympathomimetic agents, ⁇ 2 receptor agonists, ⁇ 1 receptor blockers, ⁇ receptor blockers Or a parasympathomimetic agent, a carbonic anhydrase inhibitor, a prostaglandin and a Rho kinase inhibitor, which is one or more kinds of preventive or therapeutic agents described in (1) or (2) above A preventive or therapeutic agent or an intraocular pressure reducing agent.
- prostaglandins are isopropyl unoprostone, latanoprost, travoprost, or bimatoprost.
- Rho kinase inhibitor is (R) -trans-N- (pyridin-4-yl) -4- (1-aminoethyl) cyclohexanecarboxamide, (R)-(+)-N- (1H-pyrrolo [ 2,3-b] pyridin-4-yl) -4- (1-aminoethyl) benzamide, 1- (5-isoquinolinesulfonyl) homopiperazine or 1- (5-isoquinolinesulfonyl) -2-methylpiperazine (3)
- the preventive or therapeutic agent or the intraocular pressure lowering agent according to any one of (10).
- another prophylactic or therapeutic agent for glaucoma or ocular hypertension means “another prophylactic or therapeutic agent for glaucoma or ocular hypertension” excluding tafluprost. .
- the present invention is useful as a preventive or therapeutic agent for glaucoma or ocular hypertension, and an intraocular pressure lowering agent.
- the present invention relates to (6- ⁇ [4- (pyrazol-1-yl) benzyl] (pyridin-3-ylsulfonyl) aminomethyl ⁇ pyridin-2-ylamino) isopropyl acetate represented by the following formula (1) (hereinafter, A compound for preventing or treating glaucoma or ocular hypertension in combination with one or more other glaucoma or ocular hypertension preventive or therapeutic agents, and an intraocular pressure lowering agent, which have an action on each other. Complement and / or augment.
- the present compound in the present invention can be synthesized by a method described in International Publication No. 2009/113600 or International Publication No. 2010/113957.
- the present invention is characterized in that glaucoma or ocular hypertension is prevented or treated by combining the present compound with other glaucoma or ocular hypertension preventive or therapeutic agents.
- glaucoma in the present invention primary open-angle glaucoma, normal-tension glaucoma, aqueous humor production hyperglaucoma, ocular hypertension, acute closed-angle glaucoma, chronic closed-angle glaucoma, mixed glaucoma, steroid glaucoma, amyloid glaucoma And angiogenic glaucoma, malignant glaucoma, capsular glaucoma of the lens, plateau iris syndrome and the like.
- the combination of the present compound and one or more other glaucoma or ocular hypertension preventive or therapeutic agents refers to the present compound and 1 to 3 other glaucoma or ocular hypertension preventive or therapeutic agents.
- a combination of the present compound and one or two other glaucoma or ocular hypertension preventive or therapeutic agents is more preferable.
- Any other glaucoma or ocular hypertension preventive or therapeutic agent in the present invention may be used as long as it has an intraocular pressure lowering effect and is useful for glaucoma treatment, and is a non-selective sympathomimetic agent or ⁇ 2 receptor agonist.
- the other two glaucoma or ocular hypertension prevention or treatment drugs are ⁇ receptor blockers, carbonic anhydrase inhibitors
- the agent is a prophylactic or therapeutic agent selected from the group consisting of an agent and a prostaglandin, and is a ⁇ receptor blocker and a drug carbonic anhydrase inhibitor, or a ⁇ receptor blocker and a prosta
- grangeins is more preferred.
- non-selective sympathomimetic drugs include dipivefrin
- specific examples of ⁇ 2 receptor agonists include brimonidine and apraclonidine
- specific examples of ⁇ 1 receptor blockers include bunazosin.
- Specific examples of ⁇ receptor blockers include timolol, befunolol, carteolol, nipradilol, betaxolol, levobunolol, and metipranolol
- specific examples of parasympathomimetic drugs include pilocarpine
- Specific examples of the dehydrase inhibitor include dorzolamide, brinzolamide, and acetazolamide.
- prostaglandins include prostaglandins (particularly natural prostaglandins such as prostaglandin F2 ⁇ ) disclosed in Japanese Patent Application Laid-Open No. 59-1418, Japanese Patent Publication No. 3-501025.
- Prostaglandins such as latanoprost disclosed in the publication, prostaglandins such as isopropyl unoprostone disclosed in JP-A-2-108, and disclosed in JP-A-8-501310
- Prostaglandins such as bimatoprost, prostaglandins such as travoprost disclosed in JP-A-10-182465, Surv Ophthalmol 47 (Suppl 1): AL-6598 disclosed in S13-S33, 2002 PF-047452 disclosed in Prostaglandins such as Exp Eye Res.
- prostaglandins such as, preferably among others PGF2 ⁇ or PGF2 ⁇ derivatives, isopropyl unoprostone, latanoprost, more preferably travoprost or bimatoprost.
- the Rho kinase inhibitor in the present invention means a compound that inhibits serine / threonine kinase activated with the activation of Rho.
- ROK ⁇ ROCK-II
- p160ROCK ROK ⁇
- ROCK-I p160ROCK
- Rho kinase inhibitor include (R) -trans-N- (pyridin-4-yl) -4- (1) disclosed in WO 98/06433 and WO 00/09162.
- Rho kinase inhibitors such as -aminoethyl) cyclohexanecarboxamide, (R)-(+)-N- (1H-pyrrolo [2,3-b] pyridin-4-yl) -4- (1-aminoethyl) benzamide
- 1- (5-isoquinolinesulfonyl) homopiperazine, 1- (5-isoquinolinesulfonyl) -2-methylpiperazine and the like disclosed in WO 97/23222, Nature, 389, 990-994 (1997)
- Rho kinase inhibitors are (1-benzylpyrrolidin-3-yl)-(1H-indazol-5-yl) amines disclosed in WO 01/56888
- Rho kinase inhibitors such as (1-benzylpiperidin-4-yl)-(1H-indazol-5-yl) amine are disclosed in International Publication No.
- Rho kinases such as N- [2- (4-fluorophenyl) -6,7-dimethoxy-4-quinazolinyl] -N- (1H-indazol-5-yl) amine as disclosed in publication 02/076976
- the inhibitor is N-4- (1H-indazol-5-yl) -6,7-dimethoxy-N-2-pyridin-4-yl-quinazoline-2, disclosed in WO 02/076977.
- Rho kinase inhibitors such as 4-diamine are disclosed in 4-methyl-5- (2-methyl- [1,4] diazepane--disclosed in WO 99/64011.
- Rho kinase inhibitors such as isoquinoline and the like.
- two other glaucoma or ocular hypertension preventive or therapeutic agents when combining this compound with two other glaucoma or ocular hypertension preventive or therapeutic agents include timolol and dorzolamide, timolol and Latanoprost, timolol and travoprost are mentioned.
- the present compound and other preventive or therapeutic agents for glaucoma or ocular hypertension also include salt forms. These are not particularly limited as long as they are pharmaceutically acceptable salts.
- the salts include salts with inorganic acids, salts with organic acids, quaternary ammonium salts, salts with halogen ions, salts with alkali metals, alkaline earths. Examples thereof include salts with similar metals, metal salts, salts with ammonia, and salts with organic amines.
- the salt with inorganic acid include salts with hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, sulfuric acid, phosphoric acid and the like.
- Salts with organic acids include acetic acid, oxalic acid, fumaric acid, maleic acid, succinic acid, citric acid, tartaric acid, adipic acid, gluconic acid, glucoheptic acid, glucuronic acid, terephthalic acid, methanesulfonic acid, lactic acid, hippuric acid 1,2-ethanedisulfonic acid, isethionic acid, lactobionic acid, oleic acid, pamoic acid, polygalacturonic acid, stearic acid, tannic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, lauryl sulfate, sulfuric acid And salts with methyl, naphthalenesulfonic acid, sulfosalicylic acid and the like.
- Examples of quaternary ammonium salts include salts with methyl bromide, methyl iodide and the like.
- Salts with halogen ions include salts with chloride ions, bromide ions, iodide ions, etc.
- Salts with alkali metals include salts with lithium, sodium, potassium, etc., alkaline earths
- Examples of the salt with metal include salts with calcium, magnesium and the like, and examples of the metal salt include salts with iron, zinc and the like.
- Salts with organic amines include triethylenediamine, 2-aminoethanol, 2,2-iminobis (ethanol), 1-deoxy-1- (methylamino) -2-D-sorbitol, 2-amino-2- (hydroxy And salts with methyl) -1,3-propanediol, procaine, N, N-bis (phenylmethyl) -1,2-ethanediamine and the like.
- the present compound and other preventive or therapeutic agents for glaucoma or ocular hypertension in the present invention also include derivatives such as esters and amides.
- esters include esters obtained by condensing hydroxyl groups in other glaucoma or ocular hypertension preventive or therapeutic agents with carboxylic acids such as acetic acid, propionic acid, isopropionic acid, butyric acid, isobutyric acid, and pivalic acid.
- carboxylic acids such as acetic acid, propionic acid, isopropionic acid, butyric acid, isobutyric acid, and pivalic acid.
- an ester obtained by condensing a carboxyl group in a preventive or therapeutic agent for glaucoma or ocular hypertension and an alcohol such as methanol, ethanol, propanol or isopropyl alcohol.
- amides include amino groups and carboxylic acids such as acetic acid, propionic acid, isopropionic acid, butyric acid, isobutyric acid, and pivalic acid in the present compound and / or other glaucoma or ocular hypertension preventive or therapeutic agents.
- carboxylic acids such as acetic acid, propionic acid, isopropionic acid, butyric acid, isobutyric acid, and pivalic acid in the present compound and / or other glaucoma or ocular hypertension preventive or therapeutic agents.
- condensed amides and amides obtained by condensing carboxyl groups in other glaucoma or ocular hypertension preventive or therapeutic agents and amines such as methylamine, ethylamine, propylamine, and isopropylamine.
- present compound and other preventive or therapeutic agents for glaucoma or ocular hypertension in the present invention may take the form of hydrates or solvates.
- the compound may be administered in the form of multiple preparations separately formulated with other glaucoma or ocular hypertension prevention or treatment drugs (combination administration), and each component is combined You may administer with the form (combination) made into one preparation. A combination is preferred. Furthermore, when combining this compound with a plurality of other glaucoma or ocular hypertension preventive or therapeutic agents, the respective components may be administered in combination, and this compound may be used in combination with other glaucoma or ocular hypertension. Alternatively, a mixture containing any components of the therapeutic agent and the remaining components may be administered in combination, or a mixture containing all components.
- the preparation of the present invention can be administered either orally or parenterally, and no special technique is required for preparation of these preparations, and preparations can be made using widely used techniques.
- the dosage form include eye drops, eye ointments, injections, tablets, capsules, granules, powders and the like, and eye drops or eye ointments are preferable.
- the formulations can be prepared according to known methods, respectively.
- a preparation of the present compound can be prepared with reference to the preparation examples described in International Publication No. 2009/113600 or International Publication No. 2010/113957.
- Rho kinase inhibitor preparation can be prepared with reference to the preparation examples described in International Publication No. 00/09162, International Publication No. 97/22322
- any combination of the present compound and other glaucoma or ocular hypertension preventive or therapeutic agent it can be prepared according to a known method.
- a desired eye drop is prepared by adding and stirring the present compound or other glaucoma or ocular hypertension preventive or therapeutic agent to purified water, buffer, etc., and then adjusting the pH with a pH adjuster.
- additives that are widely used for eye drops can be used as necessary, and examples of the additives include isotonic agents, buffering agents, surfactants, stabilizers, and preservatives.
- the isotonic agent include sodium chloride and concentrated glycerin
- examples of the buffering agent include sodium phosphate, sodium acetate, boric acid, borax, citric acid, and the like.
- Examples include oxyethylene sorbitan monooleate, polyoxyl stearate, and polyoxyethylene hydrogenated castor oil.
- Stabilizers include sodium citrate and sodium edetate.
- Preservatives include benzalkonium chloride and parabens. And other preservatives.
- the pH of the eye drop may be within the range acceptable for ophthalmic preparations, preferably in the range of pH 4-8, more preferably in the range of pH 5-7.
- an eye ointment it can be prepared using a widely used base, and examples of the base include white petrolatum and liquid paraffin.
- fillers, lubricants, binders, disintegrants, coating agents, coating agents, etc. can be added as necessary.
- the bulking agent include lactose, crystalline cellulose, starch, and vegetable oil
- examples of the lubricant include magnesium stearate, talc, and the like
- examples of the binder include hydroxypropyl cellulose, polyvinyl pyrrolidone, and the like.
- examples of the disintegrant include carboxymethylcellulose calcium and low-substituted hydroxypropylmethylcellulose
- examples of the coating agent include hydroxypropylmethylcellulose, macrogol, and silicone resin
- the filming agent include a gelatin film.
- the dosage of this compound and other glaucoma or ocular hypertension preventive or therapeutic agents should be changed appropriately according to the dosage form, the severity of the patient's symptoms, age, weight, route of administration, doctor's judgment, etc. Can do.
- the case of ophthalmic administration will be mainly described below as an example.
- the dose of this compound is usually in the range of 0.05 to 500 ⁇ g per day, and can be administered once or divided into several times a day.
- the patient's age, symptoms, etc. Can be increased or decreased as appropriate.
- the concentration of the present compound in the eye drop is not particularly limited, but it is within the range of 0.00001 to 3 w / v%, preferably within the range of 0.0001 to 1 w / v%, more preferably 0.001 to 0.
- Eye drops having a concentration within the range of 1 w / v%, more preferably within the range of 0.003 to 0.03 w / v% can be instilled once or several times a day.
- the concentration of the eye drop may be calculated based on the weight of any of the free form of this compound and its salt (hereinafter the same).
- the daily dose is usually within the range of 0.0001 to 30 mg, preferably within the range of 0.0003 to 10 mg, more preferably within the range of 0.001 to 3 mg. More preferably, the dose can be administered once or several times within the range of 0.003 to 1 mg.
- the dose of the non-selective sympathomimetic drug varies depending on the type of drug, but the daily dose is usually in the range of 1 to 5000 ⁇ g and can be administered once or several times a day. More specifically, in the case of dipivefrin, a daily dose of 2 to 3000 ⁇ g is usually used, and these doses can be appropriately increased or decreased depending on the age, symptoms, etc. of the patient.
- the doses of other non-selective sympathomimetic drugs can be determined based on the same criteria.
- the concentration of the non-selective sympathomimetic drug in the ophthalmic solution is not particularly limited, but in the case of dipivefrin, it is within the range of 0.001 to 3 w / v%, preferably 0.04 to 0.1 w / v%. Of ophthalmic solution at a concentration of 0.04 w / v% or 0.1 w / v%, more preferably once or several times a day.
- the dose of the ⁇ 2 receptor agonist varies depending on the type of drug, but the daily dose is usually in the range of 2 to 3000 ⁇ g, and can be administered once or several times a day. More specifically, in the case of brimonidine, a daily dose of 2 to 1000 ⁇ g is usually used, and in the case of apraclonidine, a daily dose of 20 to 3000 ⁇ g is usually used. Can be increased or decreased as appropriate.
- the doses of other ⁇ 2 receptor agonists can be determined based on the same criteria.
- the concentration of the ⁇ 2 receptor agonist in the ophthalmic solution is not particularly limited, but in the case of brimonidine, it is in the range of 0.01 to 5 w / v%, preferably 0.1 to 0.5 w / v%.
- An eye drop having a concentration within a range, more preferably 0.1 w / v%, 0.15 w / v%, 0.2 w / v% or 0.5 w / v% may be instilled once or several times a day. it can.
- the concentration is within the range of 0.01 to 5 w / v%, preferably within the range of 0.5 to 1 w / v%, more preferably 0.5 w / v% or 1 w / v%.
- the dose of ⁇ 1 receptor blocker varies depending on the type of drug, but the daily dose is usually in the range of 1 to 5000 ⁇ g, and can be administered once or divided into several times a day. More specifically, in the case of bunazosin, a daily dose of 2 to 3000 ⁇ g is usually used, and these doses can be appropriately increased or decreased depending on the age, symptoms, etc. of the patient. The doses of other ⁇ 1 receptor blockers can be determined based on the same criteria.
- the concentration of the ⁇ 1 receptor blocker in the ophthalmic solution is not particularly limited, but in the case of bunazosin, it is within the range of 0.001 to 0.3 w / v%, preferably 0.003 to 0.03 w / v. %, More preferably 0.01% w / v% of eye drops can be instilled once or several times a day.
- the dose of ⁇ receptor blocker varies depending on the type of drug, but the daily dose is usually in the range of 5 to 5000 ⁇ g and can be administered once or several times a day. More specifically, in the case of timolol, the daily dose is 5 to 1500 ⁇ g, in the case of befnolol, the daily dose is 10 to 2000 ⁇ g, and in the case of carteolol, the daily dose is 10 to 5000 ⁇ g.
- the daily dose is 10 to 1250 ⁇ g, in the case of betaxolol, the daily dose is 50 to 1000 ⁇ g, in the case of levobanolol, the daily dose is 5 to 5000 ⁇ g, and in the case of methylpranolol.
- a daily dose of 5 to 5000 ⁇ g is usually used, and these doses can be appropriately increased or decreased depending on the age and symptoms of the patient.
- the doses of other ⁇ receptor blockers can be determined based on the same criteria.
- the concentration of ⁇ receptor blocker in the eye drop is not particularly limited, but in the case of timolol, it is in the range of 0.01 to 5 w / v%, preferably in the range of 0.1 to 0.5 w / v%.
- an ophthalmic solution having a concentration of 0.1 w / v%, 0.25 w / v% or 0.5 w / v% can be instilled once or several times a day.
- befnolol it is within the range of 0.01 to 5 w / v%, preferably within the range of 0.25 to 1 w / v%, more preferably 0.25 w / v%, 0.5 w / v% or Eye drops with a concentration of 1 w / v% can be instilled once or several times a day.
- an ophthalmic solution having a concentration of 0.01 to 5 w / v%, preferably 1 to 2 w / v%, more preferably 1 w / v% or 2 w / v% is used. Can be instilled once or several times a day.
- an eye drop at a concentration of 0.01 to 5 w / v%, preferably 0.25 w / v%, can be instilled once or several times a day.
- betaxolol it is in the range of 0.01 to 5 w / v%, preferably in the range of 0.25 to 0.5 w / v%, more preferably 0.25 w / v% or 0.5 w / v%.
- levobunolol it is in the range of 0.01 to 5 w / v%, preferably in the range of 0.25 to 0.5 w / v%, more preferably 0.25 w / v% or 0.5 w / v%.
- an eye drop having a concentration of 0.01 to 5 w / v%, preferably 0.3 w / v% can be instilled once or several times a day.
- the dose of parasympathomimetic drug varies depending on the type of drug, but the daily dose is usually in the range of 5 to 300,000 ⁇ g and can be administered once or several times a day. More specifically, in the case of pilocarpine, a daily dose of 5 to 200,000 ⁇ g is usually used, and these doses can be appropriately increased or decreased depending on the age, symptoms, etc. of the patient.
- the doses of other parasympathomimetic drugs can be determined based on similar criteria.
- the concentration of the parasympathomimetic drug in the ophthalmic solution is not particularly limited, but in the case of pilocarpine, it is within the range of 0.01 to 20 w / v%, preferably within the range of 0.1 to 5 w / v%, and more Eye drops having a concentration of preferably 0.5 w / v%, 1 w / v%, 2 w / v%, 3 w / v% or 4 w / v% can be instilled once or several times a day.
- the dose of the carbonic anhydrase inhibitor varies depending on the type of drug, but the daily dose is usually in the range of 10 to 10000 ⁇ g, and can be administered once or several times a day. More specifically, in the case of dorzolamide, a daily dose of 10 to 10,000 ⁇ g is usually used, and in the case of brinzolamide, a daily dose of 20 to 5000 ⁇ g is usually used. It can be increased or decreased as appropriate. In addition, doses of other carbonic anhydrase inhibitors can be determined based on similar criteria.
- the concentration of the carbonic anhydrase inhibitor in the eye drop is not particularly limited, but in the case of dorzolamide, it is in the range of 0.01 to 5 w / v%, preferably in the range of 0.5 to 2 w / v%. More preferably, an ophthalmic solution having a concentration of 0.5 w / v%, 1 w / v% or 2 w / v% can be instilled once or several times a day. In the case of brinzolamide, an eye drop having a concentration of 0.01 to 5 w / v%, preferably 0.1 to 2 w / v%, more preferably 1 w / v% is once a day. Or it can be instilled several times.
- acetazolamide an eye drop having a concentration in the range of 0.01 to 5 w / v%, preferably in the range of 1 to 5 w / v% can be used.
- a daily dose of 250 to 1000 mg can be used.
- the dose of prostaglandins varies depending on the type of drug, but the daily dose is usually in the range of 0.1 to 1000 ⁇ g, and can be administered once or several times a day. More specifically, in the case of latanoprost, the daily dose is 1 to 5 ⁇ g, in the case of isopropyl unoprostone, the daily dose is 30 to 300 ⁇ g, and in the case of bimatoprost, the daily dose is 2 to 30 ⁇ g. However, in the case of travoprost, a daily dose of 0.5 to 5 ⁇ g is usually used, and the dose can be appropriately increased or decreased depending on the age, symptoms, etc. of the patient. The doses of other prostaglandins can be determined based on the same criteria.
- the concentration of prostaglandins in the eye drop is not particularly limited, but in the case of latanoprost, it is within the range of 0.0001 to 5 w / v%, preferably within the range of 0.0005 to 1 w / v%, more An eye drop having a concentration of preferably 0.001 to 0.1 w / v%, more preferably 0.005 w / v% can be instilled once or several times a day. In the case of isopropyl unoprostone, it is in the range of 0.001 to 5 w / v%, preferably in the range of 0.01 to 1 w / v%, more preferably in the range of 0.12 to 0.15 w / v%.
- an ophthalmic solution having a concentration of 0.12 w / v% or 0.15 w / v% can be instilled once or several times a day.
- bimatoprost it is within the range of 0.0001 to 5 w / v%, preferably within the range of 0.001 to 1 w / v%, more preferably within the range of 0.01 to 0.03 w / v%,
- an ophthalmic solution having a concentration of 0.01 w / v% or 0.03 w / v% can be applied once or several times a day.
- an ophthalmic solution having a concentration of 0.0001 to 5 w / v%, preferably 0.001 to 1 w / v%, more preferably 0.004 w / v% Can be instilled once or several times.
- the dosage of the Rho kinase inhibitor varies depending on the type of drug, but the daily dosage is usually in the range of 0.025 to 10,000 ⁇ g, and can be administered once or divided into several times a day. The dose can be appropriately increased or decreased depending on the age and symptoms of the patient.
- the concentration of the Rho kinase inhibitor in the ophthalmic solution is not particularly limited, but an ophthalmic solution having a concentration in the range of 0.0001 to 5 w / v%, preferably 0.001 to 1 w / v% is once a day or Can be instilled several times.
- glaucoma or ocular hypertension prevention or treatment drugs any of the compounds and other glaucoma or ocular hypertension prevention or treatment drugs can be used.
- a preparation is prepared by appropriately selecting the mixing ratio so that the daily dose falls within the range of the dose of each component described above, and the combined preparation is Can be administered once or divided into several times.
- the amount of the present compound is changed to 0.001 g, 0.003 g, 0.03 g, 0.1 g, etc., and the type and amount of other glaucoma or ocular hypertension preventive or therapeutic agents and additives Can be used to prepare eye drops and eye ointments of the desired combination and concentration.
- physiological saline Commercially available physiological saline (trade name: Otsuka raw food injection, obtained from Otsuka Pharmaceutical Factory Co., Ltd.) was used as it was.
- Test method The effect of lowering intraocular pressure when this compound and timolol were administered in combination was examined. For comparison, the effect of lowering intraocular pressure when this compound was administered alone or timolol was administered alone was also examined. For the control, a base and physiological saline were administered.
- the present compound solution 0.001 w / v%
- the present compound solution (eye drop amount: 50 ⁇ L)
- Timolol solution Timolol ophthalmic solution (trade name: Timoptol (registered trademark) ophthalmic solution 0.5%, ophthalmic volume: 50 ⁇ L)
- Experimental animal Japanese white rabbit (strain: JW, sex: male, 6 birds per group)
- Table 1 shows the intraocular pressure drop width (vs. the control group average value) 4 hours after instillation in each administration group.
- Intraocular pressure drop indicates the difference between the average value of intraocular pressure variation ( ⁇ IOP) from the initial intraocular pressure value of the control group and ⁇ IOP of each individual as an average value of 6 birds in each group .
- the intraocular pressure drop width (versus the control group average value) in the 4-hour post-instillation period of the combined administration group of the present compound and timolol was compared with that of the drug alone administration group, that is, the present compound administration group and timolol administration group. It is greater than the sum of the decrease in intraocular pressure for 4 hours after instillation (vs. the average value for the control group) and the sum of the decrease in intraocular pressure for 4 hours after instillation (vs. the average value for the control group)
- the combined effect of this compound and timolol was synergistic.
- Example 2 In order to examine the usefulness of the combination of this compound and prostaglandins, the effect of lowering intraocular pressure when this compound and latanoprost were administered in combination to experimental animals (normal intraocular pressure monkeys) was examined.
- physiological saline Commercially available physiological saline (trade name: Otsuka raw food injection, obtained from Otsuka Pharmaceutical Factory Co., Ltd.) was used as it was.
- Test method The effect of lowering intraocular pressure when this compound and latanoprost were administered in combination was examined. For comparison, the effect of lowering intraocular pressure when this compound was administered alone or latanoprost was also examined. For the control, a base and physiological saline were administered.
- the present compound solution 0.0006 w / v%
- the present compound solution eye drop amount: 20 ⁇ L
- Latanoprost solution Latanoprost ophthalmic solution (trade name: Xalatan (registered trademark) ophthalmic solution 0.005%, ophthalmic dose: 20 ⁇ L)
- Experimental animal cynomolgus monkey (sex: male, 6 animals per group)
- Table 2 shows the decrease in intraocular pressure (vs. control group average value) 8 hours after instillation in each administration group.
- the decrease in intraocular pressure (vs. control group average value) represents the difference between the average value of intraocular pressure fluctuation ( ⁇ IOP) from the initial intraocular pressure value of the control group and ⁇ IOP of each individual as the average value of 6 animals in each group.
- the intraocular pressure drop width (vs. the control group average value) of 8 hours after instillation in the combined administration group of the present compound and latanoprost was compared with that of the drug alone administration group, that is, the present compound administration group and the latanoprost administration group. It is larger than the intraocular pressure drop width (vs. control group average value) 8 hours after instillation and larger than the sum of the intraocular pressure drop widths (vs. control group average value) 8 hours after instillation caused by administration of each drug alone.
- the combined effect of this compound and latanoprost was synergistic.
- Example 3 In order to examine the usefulness of the combination of this compound and an ⁇ 2 receptor agonist, the effect of lowering intraocular pressure when this compound and brimonidine were administered in combination to experimental animals (normal intraocular pressure monkeys) was examined.
- physiological saline Commercially available physiological saline (trade name: Otsuka raw food injection, obtained from Otsuka Pharmaceutical Factory Co., Ltd.) was used as it was.
- Test method The effect of lowering intraocular pressure when this compound and brimonidine were administered in combination was examined. For comparison, the effect of lowering intraocular pressure when this compound was administered alone or when brimonidine was administered alone was also examined. For the control, a base and physiological saline were administered.
- the present compound solution 0.0006 w / v%
- the present compound solution eye drop amount: 20 ⁇ L
- Brimonidine solution Brimonidine ophthalmic solution (trade name: ALPHAGAN (registered trademark) P 0.15%, ophthalmic dose: 20 ⁇ L)
- Experimental animal cynomolgus monkey (sex: male, 6 animals per group)
- Table 3 shows the decrease in intraocular pressure for 2 hours after instillation (vs. control group average value) in each administration group.
- the decrease in intraocular pressure represents the difference between the average value of intraocular pressure fluctuation ( ⁇ IOP) from the initial intraocular pressure value of the control group and ⁇ IOP of each individual as the average value of 6 animals in each group.
- the intraocular pressure drop width (versus the control group average value) in the 2 hours after instillation of the combination administration group of this compound and brimonidine was compared with that of the drug alone administration group, that is, the present compound administration group and the brimonidine administration group. It is larger than the intraocular pressure decrease width (vs. control group average value) 2 hours after instillation and larger than the sum of the intraocular pressure decrease widths (vs. control group average value) 2 hours after instillation caused by administration of each drug alone.
- the combined effect of this compound and brimonidine was synergistic.
- Example 4 In order to examine the usefulness of the combination of this compound and a carbonic anhydrase inhibitor, the intraocular pressure-lowering effect when this compound and brinzolamide were administered in combination to experimental animals (normal intraocular pressure monkeys) was examined.
- physiological saline Commercially available physiological saline (trade name: Otsuka raw food injection, obtained from Otsuka Pharmaceutical Factory Co., Ltd.) was used as it was.
- Test method The effect of lowering intraocular pressure when this compound and brinzolamide were administered in combination was examined. For comparison, the effect of lowering intraocular pressure when this compound was administered alone or bronzolamide was also examined. For the control, a base and physiological saline were administered.
- the present compound solution 0.0006 w / v%
- the present compound solution eye drop amount: 20 ⁇ L
- Brinzolamide suspension Brinzolamide suspension ophthalmic solution (trade name: Ezopto (registered trademark) suspension ophthalmic solution 1%, ophthalmic dose: 20 ⁇ L)
- Experimental animal cynomolgus monkey (sex: male, 5 or 6 animals in a group)
- Table 4 shows the decrease in intraocular pressure (vs. control group average value) 4 hours after instillation in each administration group.
- Intraocular pressure drop (vs. control group average value) is the difference between the average value of intraocular pressure value fluctuation ( ⁇ IOP) from the initial intraocular pressure value of the control group and ⁇ IOP of each individual as the average value of 5 or 6 animals in each group Show.
Abstract
Description
本発明における本化合物と他の緑内障若しくは高眼圧症の予防または治療薬とを配合した点眼剤と眼軟膏の具体的な製剤例を以下に示す。
点眼剤(100mL中)
本化合物 0.01g
塩酸ジピベフリン 0.04g
リン酸二水素ナトリウム 0.15g
グリセリン 適量
ポリオキシル35ヒマシ油 1.7g
エデト酸ナトリウム 0.05g
塩化ベンザルコニウム 0.005g
希塩酸 適量
水酸化ナトリウム 適量
精製水 適量
点眼剤(100mL中)
本化合物 0.01g
マレイン酸チモロール 0.25g
リン酸二水素ナトリウム 0.15g
グリセリン 適量
ポリオキシル35ヒマシ油 1.7g
エデト酸ナトリウム 0.05g
塩化ベンザルコニウム 0.005g
希塩酸 適量
水酸化ナトリウム 適量
精製水 適量
点眼剤(100mL中)
本化合物 0.01g
マレイン酸チモロール 0.5g
リン酸二水素ナトリウム 0.15g
グリセリン 適量
ポリオキシル35ヒマシ油 1.7g
エデト酸ナトリウム 0.05g
塩化ベンザルコニウム 0.005g
希塩酸 適量
水酸化ナトリウム 適量
精製水 適量
点眼剤(100mL中)
本化合物 0.01g
塩酸ドルゾラミド 0.5g
リン酸二水素ナトリウム 0.15g
グリセリン 適量
ポリオキシル35ヒマシ油 1.7g
エデト酸ナトリウム 0.05g
塩化ベンザルコニウム 0.005g
希塩酸 適量
水酸化ナトリウム 適量
精製水 適量
点眼剤(100mL中)
本化合物 0.01g
ブリンゾラミド 1g
リン酸二水素ナトリウム 0.15g
グリセリン 適量
ポリオキシル35ヒマシ油 1.7g
エデト酸ナトリウム 0.05g
塩化ベンザルコニウム 0.005g
希塩酸 適量
水酸化ナトリウム 適量
精製水 適量
点眼剤(100mL中)
本化合物 0.01g
塩酸ドルゾラミド 1g
マレイン酸チモロール 0.5g
リン酸二水素ナトリウム 0.15g
グリセリン 適量
ポリオキシル35ヒマシ油 1.7g
エデト酸ナトリウム 0.05g
塩化ベンザルコニウム 0.005g
希塩酸 適量
水酸化ナトリウム 適量
精製水 適量
点眼剤(100mL中)
本化合物 0.01g
イソプロピルウノプロストン 0.12g
リン酸二水素ナトリウム 0.15g
グリセリン 適量
ポリオキシル35ヒマシ油 1.7g
エデト酸ナトリウム 0.05g
塩化ベンザルコニウム 0.005g
希塩酸 適量
水酸化ナトリウム 適量
精製水 適量
点眼剤(100mL中)
本化合物 0.01g
ラタノプロスト 0.005g
リン酸二水素ナトリウム 0.15g
グリセリン 適量
ポリオキシル35ヒマシ油 1.7g
エデト酸ナトリウム 0.05g
塩化ベンザルコニウム 0.005g
希塩酸 適量
水酸化ナトリウム 適量
精製水 適量
点眼剤(100mL中)
本化合物 0.01g
ビマトプロスト 0.01g
リン酸二水素ナトリウム 0.15g
グリセリン 適量
ポリオキシル35ヒマシ油 1.7g
エデト酸ナトリウム 0.05g
塩化ベンザルコニウム 0.005g
希塩酸 適量
水酸化ナトリウム 適量
精製水 適量
点眼剤(100mL中)
本化合物 0.01g
トラボプロスト 0.004g
リン酸二水素ナトリウム 0.15g
グリセリン 適量
ポリオキシル35ヒマシ油 1.7g
エデト酸ナトリウム 0.05g
塩化ベンザルコニウム 0.005g
希塩酸 適量
水酸化ナトリウム 適量
精製水 適量
点眼剤(100mL中)
本化合物 0.01g
ラタノプロスト 0.005g
マレイン酸チモロール 0.5g
リン酸二水素ナトリウム 0.15g
グリセリン 適量
ポリオキシル35ヒマシ油 1.7g
エデト酸ナトリウム 0.05g
塩化ベンザルコニウム 0.005g
希塩酸 適量
水酸化ナトリウム 適量
精製水 適量
点眼剤(100mL中)
本化合物 0.01g
酒石酸ブリモニジン 0.1g
リン酸二水素ナトリウム 0.15g
グリセリン 適量
ポリオキシル35ヒマシ油 1.7g
エデト酸ナトリウム 0.05g
塩化ベンザルコニウム 0.005g
希塩酸 適量
水酸化ナトリウム 適量
精製水 適量
点眼剤(100mL中)
本化合物 0.01g
酒石酸ブリモニジン 0.2g
リン酸二水素ナトリウム 0.15g
グリセリン 適量
ポリオキシル35ヒマシ油 1.7g
エデト酸ナトリウム 0.05g
塩化ベンザルコニウム 0.005g
希塩酸 適量
水酸化ナトリウム 適量
精製水 適量
点眼剤(100mL中)
本化合物 0.01g
塩酸ブナゾシン 0.01g
リン酸二水素ナトリウム 0.15g
グリセリン 適量
ポリオキシル35ヒマシ油 1.7g
エデト酸ナトリウム 0.05g
塩化ベンザルコニウム 0.005g
希塩酸 適量
水酸化ナトリウム 適量
精製水 適量
点眼剤(100mL中)
本化合物 0.01g
塩酸ピロカルピン 0.5g
リン酸二水素ナトリウム 0.15g
グリセリン 適量
ポリオキシル35ヒマシ油 1.7g
エデト酸ナトリウム 0.05g
塩化ベンザルコニウム 0.005g
希塩酸 適量
水酸化ナトリウム 適量
精製水 適量
眼軟膏(100g中)
本化合物 0.01g
マレイン酸チモロール 0.5g
流動パラフィン 10.0g
白色ワセリン 適量
眼軟膏(100g中)
本化合物 0.01g
イソプロピルウノプロストン 0.12g
流動パラフィン 10.0g
白色ワセリン 適量
眼軟膏(100g中)
本化合物 0.01g
ラタノプロスト 0.005g
流動パラフィン 10.0g
白色ワセリン 適量
[実施例1]
本化合物とβ受容体遮断薬との組み合わせの有用性を調べるため、実験動物(正常眼圧ウサギ)に本化合物とチモロールを併用投与したときの眼圧下降効果を検討した。
(1)基剤の調製
ポリオキシル35ヒマシ油1.7gに0.5%エデト酸ナトリウム/10%グリセリン溶液10mL、1%塩化ベンザルコニウム溶液1mL、精製水30mL、2%ホウ酸/0.2%ソルビン酸溶液50mLを加え溶解した。溶液を確認後、これに水酸化ナトリウム溶液もしくは希塩酸を適量加え、製剤のpHを6.5前後とした後、精製水を適量加えて全量を100mLとした。
ポリオキシル35ヒマシ油0.8gに本化合物0.001gを加え、0.5%エデト酸ナトリウム/10%グリセリン溶液10mL、1%塩化ベンザルコニウム溶液1mL、精製水30mL、2%ホウ酸/0.2%ソルビン酸溶液50mLを加え溶解した。溶液を確認後、これに水酸化ナトリウム溶液もしくは希塩酸を適量加え、製剤のpHを6.5前後とした後、精製水を適量加えて全量を100mLとした。
市販の生理食塩液(商品名:大塚生食注、株式会社大塚製薬工場より入手)をそのまま使用した。
市販のチモロール点眼液をそのまま使用した。
本化合物とチモロールとを併用投与したときの眼圧下降効果を検討した。比較対象として、本化合物を単独投与またはチモロールを単独投与したときの眼圧下降効果についても検討した。コントロールには基剤および生理食塩水を投与した。
本化合物溶液:0.001w/v% 本化合物溶液(点眼量:50μL)
チモロール溶液:チモロール点眼液(商品名:チモプトール(登録商標)点眼液0.5%、点眼量:50μL)
実験動物:日本白色ウサギ(系統:JW、性別:雄性、一群6羽)
〔1〕本化合物とチモロールとの併用投与
(1)0.4%塩酸オキシブプロカイン点眼液(商品名:ベノキシール(登録商標)点眼液0.4%)を実験動物の両眼に一滴点眼し局所麻酔をした。
チモロール溶液を生理食塩水に代え、他は上記併用投与試験と同じ方法で試験をした。
本化合物溶液を基剤に代え、他は上記併用投与試験と同じ方法で試験をした。
本化合物溶液を基剤に、チモロール溶液を生理食塩水に代え、他は上記併用投与試験と同じ方法で試験をした。
各投与群の点眼後4時間の眼圧下降幅(対コントロール群平均値)を表1に示す。眼圧下降幅(対コントロール群平均値)は、コントロール群の初期眼圧値からの眼圧値変動幅(ΔIOP)の平均値と各個体のΔIOPの差を各群ともに6羽の平均値で示す。
本化合物とプロスタグランジン類との組み合わせの有用性を調べるため、実験動物(正常眼圧サル)に本化合物とラタノプロストを併用投与したときの眼圧下降効果を検討した。
(1)基剤の調製
ポリオキシル35ヒマシ油1.7gに0.5%エデト酸ナトリウム/10%グリセリン溶液10mL、1%塩化ベンザルコニウム溶液1mL、精製水30mL、2%ホウ酸/0.2%ソルビン酸溶液50mLを加え溶解した。溶液を確認後、これに水酸化ナトリウム溶液もしくは希塩酸を適量加え、製剤のpHを6.5前後とした後、精製水を適量加えて全量を100mLとした。
ポリオキシル35ヒマシ油0.8gに本化合物0.0006gを加え、0.5%エデト酸ナトリウム/10%グリセリン溶液10mL、1%塩化ベンザルコニウム溶液1mL、精製水30mL、2%ホウ酸/0.2%ソルビン酸溶液50mLを加え溶解した。溶液を確認後、これに水酸化ナトリウム溶液もしくは希塩酸を適量加え、製剤のpHを6.5前後とした後、精製水を適量加えて全量を100mLとした。
市販の生理食塩液(商品名:大塚生食注、株式会社大塚製薬工場より入手)をそのまま使用した。
市販のラタノプロスト点眼液をそのまま使用した。
本化合物とラタノプロストとを併用投与した時の眼圧下降効果を検討した。比較対象として、本化合物を単独投与またはラタノプロストを単独投与した時の眼圧下降効果についても検討した。コントロールには基剤および生理食塩水を投与した。
本化合物溶液:0.0006w/v% 本化合物溶液(点眼量:20μL)
ラタノプロスト溶液:ラタノプロスト点眼液(商品名:キサラタン(登録商標)点眼液0.005%、点眼量:20μL)
実験動物:カニクイザル(性別:雄性、一群6頭)
〔1〕本化合物とラタノプロストとの併用投与
(1)0.4%塩酸オキシブプロカイン点眼液(商品名:ベノキシール(登録商標)点眼液0.4%)を実験動物の両眼に一滴点眼し局所麻酔をした。
ラタノプロスト溶液を生理食塩水に代え、他は上記併用投与試験と同じ方法で試験をした。
本化合物溶液を基剤に代え、他は上記併用投与試験と同じ方法で試験をした。
本化合物溶液を基剤に、ラタノプロスト溶液を生理食塩水に代え、他は上記併用投与試験と同じ方法で試験をした。
各投与群の点眼後8時間の眼圧下降幅(対コントロール群平均値)を表2に示す。眼圧下降幅(対コントロール群平均値)は、コントロール群の初期眼圧値からの眼圧値変動幅(ΔIOP)の平均値と各個体のΔIOPの差を各群6頭の平均値で示す。
本化合物とα2受容体作動薬との組み合わせの有用性を調べるため、実験動物(正常眼圧サル)に本化合物とブリモニジンを併用投与したときの眼圧下降効果を検討した。
(1)基剤の調製
ポリオキシル35ヒマシ油1.7gに0.5%エデト酸ナトリウム/10%グリセリン溶液10mL、1%塩化ベンザルコニウム溶液1mL、精製水30mL、2%ホウ酸/0.2%ソルビン酸溶液50mLを加え溶解した。溶液を確認後、これに水酸化ナトリウム溶液もしくは希塩酸を適量加え、製剤のpHを6.5前後とした後、精製水を適量加えて全量を100mLとした。
ポリオキシル35ヒマシ油0.8gに本化合物0.0006gを加え、0.5%エデト酸ナトリウム/10%グリセリン溶液10mL、1%塩化ベンザルコニウム溶液1mL、精製水30mL、2%ホウ酸/0.2%ソルビン酸溶液50mLを加え溶解した。溶液を確認後、これに水酸化ナトリウム溶液もしくは希塩酸を適量加え、製剤のpHを6.5前後とした後、精製水を適量加えて全量を100mLとした。
市販の生理食塩液(商品名:大塚生食注、株式会社大塚製薬工場より入手)をそのまま使用した。
市販のブリモニジン点眼液をそのまま使用した。
本化合物とブリモニジンとを併用投与した時の眼圧下降効果を検討した。比較対象として、本化合物を単独投与またはブリモニジンを単独投与した時の眼圧下降効果についても検討した。コントロールには基剤および生理食塩水を投与した。
本化合物溶液:0.0006w/v% 本化合物溶液(点眼量:20μL)
ブリモニジン溶液:ブリモニジン点眼液(商品名:ALPHAGAN(登録商標)P 0.15%、点眼量:20μL)
実験動物:カニクイザル(性別:雄性、一群6頭)
〔1〕本化合物とブリモニジンとの併用投与
(1)0.4%塩酸オキシブプロカイン点眼液(商品名:ベノキシール(登録商標)点眼液0.4%)を実験動物の両眼に一滴点眼し局所麻酔をした。
ブリモニジン溶液を生理食塩水に代え、他は上記併用投与試験と同じ方法で試験をした。
本化合物溶液を基剤に代え、他は上記併用投与試験と同じ方法で試験をした。
本化合物溶液を基剤に、ブリモニジン溶液を生理食塩水に代え、他は上記併用投与試験と同じ方法で試験をした。
各投与群の点眼後2時間の眼圧下降幅(対コントロール群平均値)を表3に示す。眼圧下降幅(対コントロール群平均値)は、コントロール群の初期眼圧値からの眼圧値変動幅(ΔIOP)の平均値と各個体のΔIOPの差を各群6頭の平均値で示す。
本化合物と炭酸脱水酵素阻害剤との組み合わせの有用性を調べるため、実験動物(正常眼圧サル)に本化合物とブリンゾラミドを併用投与したときの眼圧下降効果を検討した。
(1)基剤の調製
ポリオキシル35ヒマシ油1.7gに0.5%エデト酸ナトリウム/10%グリセリン溶液10mL、1%塩化ベンザルコニウム溶液1mL、精製水30mL、2%ホウ酸/0.2%ソルビン酸溶液50mLを加え溶解した。溶液を確認後、これに水酸化ナトリウム溶液もしくは希塩酸を適量加え、製剤のpHを6.5前後とした後、精製水を適量加えて全量を100mLとした。
ポリオキシル35ヒマシ油0.8gに本化合物0.0006gを加え、0.5%エデト酸ナトリウム/10%グリセリン溶液10mL、1%塩化ベンザルコニウム溶液1mL、精製水30mL、2%ホウ酸/0.2%ソルビン酸溶液50mLを加え溶解した。溶液を確認後、これに水酸化ナトリウム溶液もしくは希塩酸を適量加え、製剤のpHを6.5前後とした後、精製水を適量加えて全量を100mLとした。
市販の生理食塩液(商品名:大塚生食注、株式会社大塚製薬工場より入手)をそのまま使用した。
市販のブリンゾラミド点眼液をそのまま使用した。
本化合物とブリンゾラミドとを併用投与した時の眼圧下降効果を検討した。比較対象として、本化合物を単独投与またはブリンゾラミドを単独投与した時の眼圧下降効果についても検討した。コントロールには基剤および生理食塩水を投与した。
本化合物溶液:0.0006w/v% 本化合物溶液(点眼量:20μL)
ブリンゾラミド懸濁液:ブリンゾラミド懸濁性点眼液(商品名:エイゾプト(登録商標)懸濁性点眼液 1%、点眼量:20μL)
実験動物:カニクイザル(性別:雄性、一群5もしくは6頭)
〔1〕本化合物とブリンゾラミドとの併用投与
(1)0.4%塩酸オキシブプロカイン点眼液(商品名:ベノキシール(登録商標)点眼液0.4%)を実験動物の両眼に一滴点眼し局所麻酔をした。
ブリンゾラミド懸濁液を生理食塩水に代え、他は上記併用投与試験と同じ方法で試験をした。
本化合物溶液を基剤に代え、他は上記併用投与試験と同じ方法で試験をした。
本化合物溶液を基剤に、ブリンゾラミド溶液を生理食塩水に代え、他は上記併用投与試験と同じ方法で試験をした。
各投与群の点眼後4時間の眼圧下降幅(対コントロール群平均値)を表4に示す。眼圧下降幅(対コントロール群平均値)は、コントロール群の初期眼圧値からの眼圧値変動幅(ΔIOP)の平均値と各個体のΔIOPの差を各群5もしくは6頭の平均値で示す。
Claims (11)
- (6-{[4-(ピラゾール-1-イル)ベンジル](ピリジン-3-イルスルホニル)アミノメチル}ピリジン-2-イルアミノ)酢酸イソプロピルと1または複数種の他の緑内障若しくは高眼圧症の予防または治療薬(ただしタフルプロストを除く)とを組み合わせた緑内障若しくは高眼圧症の予防または治療剤。
- (6-{[4-(ピラゾール-1-イル)ベンジル](ピリジン-3-イルスルホニル)アミノメチル}ピリジン-2-イルアミノ)酢酸イソプロピルと1または複数種の他の緑内障若しくは高眼圧症の予防または治療薬(ただしタフルプロストを除く)とを組み合わせた眼圧下降剤。
- 他の緑内障若しくは高眼圧症の予防または治療薬が、非選択性交感神経作動薬、α2受容体作動薬、α1受容体遮断薬、β受容体遮断薬、副交感神経作動薬、炭酸脱水酵素阻害剤、プロスタグランジン類及びRhoキナーゼ阻害剤からなる群より選択される1または複数種の予防または治療剤である、請求項1または2に記載の予防若しくは治療剤又は眼圧下降剤。
- 非選択性交感神経作動薬がジピベフリンである請求項3に記載の予防若しくは治療剤又は眼圧下降剤。
- α2受容体作動薬がブリモニジンまたはアプラクロニジンである請求項3または4に記載の予防若しくは治療剤又は眼圧下降剤。
- α1受容体遮断薬がブナゾシンである請求項3~5のいずれかに記載の予防若しくは治療剤又は眼圧下降剤。
- β受容体遮断薬がチモロール、ベフノロール、カルテオロール、ニプラジロール、ベタキソロール、レボブノロールまたはメチプラノロールである請求項3~6のいずれかに記載の予防若しくは治療剤又は眼圧下降剤。
- 副交感神経作動薬がピロカルピンである請求項3~7のいずれかに記載の予防若しくは治療剤又は眼圧下降剤。
- 炭酸脱水酵素阻害剤がドルゾラミド、ブリンゾラミドまたはアセタゾラミドである請求項3~8のいずれかに記載の予防若しくは治療剤又は眼圧下降剤。
- プロスタグランジン類がイソプロピルウノプロストン、ラタノプロスト、トラボプロストまたはビマトプロストである請求項3~9のいずれかに記載の予防若しくは治療剤又は眼圧下降剤。
- Rhoキナーゼ阻害剤が(R)-トランス-N-(ピリジン-4-イル)-4-(1-アミノエチル)シクロヘキサンカルボキサミド、(R)-(+)-N-(1H-ピロロ[2,3-b]ピリジン-4-イル)-4-(1-アミノエチル)ベンズアミド、1-(5-イソキノリンスルホニル)ホモピペラジンまたは1-(5-イソキノリンスルホニル)-2-メチルピペラジンである請求項3~10のいずれかに記載の予防若しくは治療剤又は眼圧下降剤。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020157002710A KR102074020B1 (ko) | 2012-07-13 | 2013-07-11 | 술폰아미드 화합물의 조합 |
CA2878370A CA2878370C (en) | 2012-07-13 | 2013-07-11 | Combinations comprising a sulfonamide compound for the treatment of glaucoma or ocular hypertension |
PH12015500025A PH12015500025A1 (en) | 2012-07-13 | 2015-01-06 | Sulfonamide compound combination |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012157204 | 2012-07-13 | ||
JP2012-157204 | 2012-07-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014010654A2 true WO2014010654A2 (ja) | 2014-01-16 |
WO2014010654A3 WO2014010654A3 (ja) | 2014-03-06 |
Family
ID=49916622
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/068927 WO2014010654A2 (ja) | 2012-07-13 | 2013-07-11 | スルホンアミド化合物の組み合わせ |
Country Status (6)
Country | Link |
---|---|
JP (3) | JP6193655B2 (ja) |
KR (1) | KR102074020B1 (ja) |
CA (2) | CA3099517C (ja) |
PH (1) | PH12015500025A1 (ja) |
TW (1) | TWI643619B (ja) |
WO (1) | WO2014010654A2 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015105144A1 (ja) * | 2014-01-10 | 2015-07-16 | 参天製薬株式会社 | ピリジルアミノ酢酸化合物を含む医薬製剤 |
WO2015105134A1 (ja) * | 2014-01-10 | 2015-07-16 | 参天製薬株式会社 | ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物 |
WO2015105135A1 (ja) * | 2014-01-10 | 2015-07-16 | 参天製薬株式会社 | ピリジルアミノ酢酸化合物含有医薬組成物 |
EP3199160A4 (en) * | 2014-09-25 | 2018-04-25 | Kowa Company, Ltd. | Aqueous composition |
WO2018230713A1 (ja) | 2017-06-16 | 2018-12-20 | 学校法人同志社 | カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用 |
CN111491636A (zh) * | 2017-12-21 | 2020-08-04 | 参天制药株式会社 | 奥米帕格的组合 |
CN111526876A (zh) * | 2017-12-28 | 2020-08-11 | 参天制药株式会社 | 含有吡啶基氨基乙酸化合物的药物制剂 |
US11433090B2 (en) | 2017-06-16 | 2022-09-06 | The Doshisha | mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014010654A2 (ja) * | 2012-07-13 | 2014-01-16 | 参天製薬株式会社 | スルホンアミド化合物の組み合わせ |
RU2749952C2 (ru) * | 2015-07-01 | 2021-06-21 | Сантэн Фармасьютикал Ко., Лтд. | Депо-препарат, содержащий сложный эфир лимонной кислоты |
US20180200239A1 (en) * | 2015-07-09 | 2018-07-19 | Santen Pharmaceutical Co., Ltd. | Prophylactic and/or therapeutic agent containing pyridylaminoacetic acid compound |
WO2017146036A1 (ja) * | 2016-02-22 | 2017-08-31 | 参天製薬株式会社 | ドルゾラミドとブリモニジンを含む医薬組成物 |
WO2019124489A1 (ja) * | 2017-12-21 | 2019-06-27 | 参天製薬株式会社 | セペタプロストとep2アゴニストとの組み合わせ医薬 |
JP2020033290A (ja) * | 2018-08-29 | 2020-03-05 | 興和株式会社 | 水性組成物 |
TWI777325B (zh) | 2019-12-31 | 2022-09-11 | 財團法人工業技術研究院 | β-胺基酸衍生物、含其之激酶抑制劑與醫藥組成物以及其用途 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63313728A (ja) * | 1987-04-03 | 1988-12-21 | ザ・トラステイーズ・オブ・コロンビア・ユニヴアーシテイ・イン・ザ・シテイ・オブ・ニユー・ヨーク | プロスタグランジンとアドレナリン性遮断剤との組合せからなる眼圧降下用組成物 |
JPH0565227A (ja) * | 1991-03-01 | 1993-03-19 | Ueno Seiyaku Oyo Kenkyusho:Kk | 医薬組成物 |
WO2003063879A1 (fr) * | 2002-01-29 | 2003-08-07 | Santen Pharmaceutical Co., Ltd. | Remedes contre le glaucome contenant de la bunazosine et des prostaglandines |
WO2004019951A1 (ja) * | 2002-08-29 | 2004-03-11 | Santen Pharmaceutical Co., Ltd. | Rhoキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤 |
JP2007119388A (ja) * | 2005-10-27 | 2007-05-17 | Ono Pharmaceut Co Ltd | Ep2アゴニストと血管収縮薬を組み合わせてなる安全性の高い緑内障治療剤 |
WO2010113957A1 (ja) * | 2009-03-30 | 2010-10-07 | 宇部興産株式会社 | 緑内障の治療又は予防のための医薬組成物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2372572T3 (es) * | 1998-08-17 | 2012-01-23 | Senju Pharmaceutical Co., Ltd. | Agente para profilaxis y tratamiento de glaucoma. |
WO2014010654A2 (ja) * | 2012-07-13 | 2014-01-16 | 参天製薬株式会社 | スルホンアミド化合物の組み合わせ |
-
2013
- 2013-07-11 WO PCT/JP2013/068927 patent/WO2014010654A2/ja active Application Filing
- 2013-07-11 KR KR1020157002710A patent/KR102074020B1/ko active IP Right Grant
- 2013-07-11 CA CA3099517A patent/CA3099517C/en active Active
- 2013-07-11 JP JP2013145060A patent/JP6193655B2/ja active Active
- 2013-07-11 CA CA2878370A patent/CA2878370C/en active Active
- 2013-07-11 TW TW102124846A patent/TWI643619B/zh active
-
2015
- 2015-01-06 PH PH12015500025A patent/PH12015500025A1/en unknown
-
2017
- 2017-07-14 JP JP2017137920A patent/JP6383058B2/ja active Active
-
2018
- 2018-08-02 JP JP2018145783A patent/JP6667583B2/ja active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63313728A (ja) * | 1987-04-03 | 1988-12-21 | ザ・トラステイーズ・オブ・コロンビア・ユニヴアーシテイ・イン・ザ・シテイ・オブ・ニユー・ヨーク | プロスタグランジンとアドレナリン性遮断剤との組合せからなる眼圧降下用組成物 |
JPH0565227A (ja) * | 1991-03-01 | 1993-03-19 | Ueno Seiyaku Oyo Kenkyusho:Kk | 医薬組成物 |
WO2003063879A1 (fr) * | 2002-01-29 | 2003-08-07 | Santen Pharmaceutical Co., Ltd. | Remedes contre le glaucome contenant de la bunazosine et des prostaglandines |
WO2004019951A1 (ja) * | 2002-08-29 | 2004-03-11 | Santen Pharmaceutical Co., Ltd. | Rhoキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤 |
JP2007119388A (ja) * | 2005-10-27 | 2007-05-17 | Ono Pharmaceut Co Ltd | Ep2アゴニストと血管収縮薬を組み合わせてなる安全性の高い緑内障治療剤 |
WO2010113957A1 (ja) * | 2009-03-30 | 2010-10-07 | 宇部興産株式会社 | 緑内障の治療又は予防のための医薬組成物 |
Non-Patent Citations (1)
Title |
---|
WANG, R.-F. ET AL.: 'Effect of latanoprost or 8-iso prostaglandin E2 alone and in combination on intraocular pressure in glaucomatous monkey eyes' ARCH. OPHTHALMOL. vol. 118, no. 1, 2000, pages 74 - 77 * |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA031813B1 (ru) * | 2014-01-10 | 2019-02-28 | Сантэн Фармасьютикал Ко., Лтд. | Фармацевтическая композиция, содержащая соединение пиридиламиноуксусной кислоты |
US10702511B2 (en) | 2014-01-10 | 2020-07-07 | Santen Pharmaceutical Co., Ltd. | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
EP3750541A1 (en) * | 2014-01-10 | 2020-12-16 | Santen Pharmaceutical Co., Ltd | Pharmaceutical preparation containing pyridylaminoacetic acid compound |
US10765750B2 (en) | 2014-01-10 | 2020-09-08 | Santen Pharmaceutical Co., Ltd. | Pharmaceutical composition containing pyridylaminoacetic acid compound |
EA031723B1 (ru) * | 2014-01-10 | 2019-02-28 | Сантэн Фармасьютикал Ко., Лтд. | Фармацевтическая композиция, содержащая соединение пиридиламиноуксусной кислоты и полиоксиэтиленовое касторовое масло |
US10149908B2 (en) | 2014-01-10 | 2018-12-11 | Santen Pharmaceutical Co., Ltd. | Pharmaceutical composition containing pyridylaminoacetic acid compound |
WO2015105144A1 (ja) * | 2014-01-10 | 2015-07-16 | 参天製薬株式会社 | ピリジルアミノ酢酸化合物を含む医薬製剤 |
EP3424503A1 (en) * | 2014-01-10 | 2019-01-09 | Santen Pharmaceutical Co., Ltd | Pharmaceutical preparation including pyridylamino acetic acid compound |
US10179127B2 (en) | 2014-01-10 | 2019-01-15 | Santen Pharmaceutical Co., Ltd. | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
EA031734B1 (ru) * | 2014-01-10 | 2019-02-28 | Сантен Фармасьютикал Ко., Лтд. | Фармацевтический препарат, содержащий соединение пиридиламиноуксусной кислоты |
WO2015105135A1 (ja) * | 2014-01-10 | 2015-07-16 | 参天製薬株式会社 | ピリジルアミノ酢酸化合物含有医薬組成物 |
USRE48183E1 (en) | 2014-01-10 | 2020-09-01 | Santen Pharmaceutical Co., Ltd. | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
US9943510B2 (en) | 2014-01-10 | 2018-04-17 | Santen Pharmaceutical Co., Ltd. | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
AU2015205179B2 (en) * | 2014-01-10 | 2019-09-19 | Santen Pharmaceutical Co., Ltd. | Pharmaceutical composition containing pyridylamino acetic acid compound |
AU2015205188B2 (en) * | 2014-01-10 | 2019-11-14 | Santen Pharmaceutical Co., Ltd. | Pharmaceutical preparation containing pyridylamino acetic acid compound |
US10485872B2 (en) | 2014-01-10 | 2019-11-26 | Santen Pharmaceutical Co., Ltd. | Pharmaceutical composition containing pyridylaminoacetic acid compound |
WO2015105134A1 (ja) * | 2014-01-10 | 2015-07-16 | 参天製薬株式会社 | ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物 |
US11793798B2 (en) | 2014-01-10 | 2023-10-24 | Santen Pharmaceutical Co., Ltd. | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
US11197849B2 (en) | 2014-01-10 | 2021-12-14 | Santen Pharmaceutical Co., Ltd. | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
EP3199160A4 (en) * | 2014-09-25 | 2018-04-25 | Kowa Company, Ltd. | Aqueous composition |
US10376523B2 (en) | 2014-09-25 | 2019-08-13 | Kowa Company, Ltd. | Aqueous composition containing ripasudil, or a salt, or a solvate thereof |
WO2018230713A1 (ja) | 2017-06-16 | 2018-12-20 | 学校法人同志社 | カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用 |
US11433090B2 (en) | 2017-06-16 | 2022-09-06 | The Doshisha | mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof |
CN111491636A (zh) * | 2017-12-21 | 2020-08-04 | 参天制药株式会社 | 奥米帕格的组合 |
CN111526876A (zh) * | 2017-12-28 | 2020-08-11 | 参天制药株式会社 | 含有吡啶基氨基乙酸化合物的药物制剂 |
Also Published As
Publication number | Publication date |
---|---|
KR102074020B1 (ko) | 2020-02-05 |
JP2014031369A (ja) | 2014-02-20 |
TW201408297A (zh) | 2014-03-01 |
JP6383058B2 (ja) | 2018-08-29 |
PH12015500025B1 (en) | 2015-02-23 |
JP2018165285A (ja) | 2018-10-25 |
WO2014010654A3 (ja) | 2014-03-06 |
CA2878370C (en) | 2021-01-19 |
JP6193655B2 (ja) | 2017-09-06 |
JP2017186375A (ja) | 2017-10-12 |
PH12015500025A1 (en) | 2015-02-23 |
CA3099517C (en) | 2022-04-26 |
KR20150036320A (ko) | 2015-04-07 |
TWI643619B (zh) | 2018-12-11 |
JP6667583B2 (ja) | 2020-03-18 |
CA3099517A1 (en) | 2014-01-16 |
CA2878370A1 (en) | 2014-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6383058B2 (ja) | スルホンアミド化合物の組み合わせ | |
JP5174777B2 (ja) | Rhoキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤 | |
US11974994B2 (en) | Agent for treating or preventing glaucoma including a sulfonamide compound and another drug | |
JP4934653B2 (ja) | Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤 | |
JP2014019650A (ja) | スルホンアミド化合物とタフルプロストの組み合わせ | |
US20140018350A1 (en) | Combination of sulfonamide compound and tafluprost | |
JP4482726B2 (ja) | Rhoキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤 | |
JP2023110030A (ja) | セペタプロストとRhoキナーゼ阻害剤との組み合わせ医薬 | |
WO2019131901A1 (ja) | ピリジルアミノ酢酸化合物を含有する医薬製剤 | |
JP2012250951A (ja) | アデノシン誘導体とプロスタグランジン類とβ受容体遮断薬の組合せ剤 | |
JP2012250947A (ja) | アデノシン誘導体とβ受容体遮断薬の組合せ剤 | |
JP2012250949A (ja) | アデノシン誘導体と炭酸脱水酵素阻害剤とβ受容体遮断薬の組合せ剤 | |
JP2012250953A (ja) | アデノシン誘導体とα2受容体作動薬の組合せ剤 | |
JP2023110029A (ja) | オミデネパグの組合せ | |
JP2012250952A (ja) | アデノシン誘導体とRhoキナーゼ阻害剤の組合せ剤 | |
JP2012250948A (ja) | アデノシン誘導体と炭酸脱水酵素阻害剤の組合せ剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13816480 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2878370 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12015500025 Country of ref document: PH |
|
ENP | Entry into the national phase |
Ref document number: 20157002710 Country of ref document: KR Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13816480 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |